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A B S T R A C T
Treatment of infection in clinical orthopaedic and trauma care is a time consuming and costly endeavour.
More than once, it will lead to extraction of implant material and additional surgical interventions.
Currently, debridement, implantation of PMMA beads impregnated with antibiotics most often with
implant exchange are the gold standard for deep infection treatment. Recently bone graft substitute
materials such as calcium phosphate, collagen ﬂeeces and bioglasses have appeared for speciﬁc use in
infection treatment. Although these materials show great potential, their supporting level of evidence is
still limited.
This review paper provides an overview of current understanding and therapies for infection
treatment and provides concepts for the use of new developed biomaterials in infection treatment.
Furthermore, the beneﬁts and risks of using biomaterials in infection treatment are discussed and the
level of evidence of a number of new materials is presented.
 2011 Elsevier Ltd. 
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Implants are nowadays routinely used in orthopaedics and
traumatology, ranging from simple screws, biomaterials and
bone substitutes to total joint arthroplasties. Infections are
fortunately rare but difﬁcult to treat and due to ever increasing
numbers of implants being used as well as an increase in
antibiotic resistant bacteria strains,1 absolute numbers of
infection are on the rise.
The incidence of infection after total joint arthroplasty ranges
from 1% or less2,3 in primaries, to 5% in revision settings and 20% or
more when revising for infection.4 Traumatologic interventions
show somewhat higher numbers, due to involvement of open
fracture treatment.5,6
Morbidity, mortality and cost of treatment are severely
inﬂuenced by the occurrence of infection and therefore infection
related to implants remains a challenge.7 There is also increasing
evidence that many revision that are deemed ‘‘aseptic’’ at workup,
are in fact infected.8
The herein study provides an overview of current understand-
ing and therapies for infection treatment and provides concepts for
the use of new developed biomaterials in infection treatment.
Furthermore, the beneﬁts and risks of using biomaterials in
infection treatment are discussed and the level of evidence of a
number of new materials is presented.* Corresponding author. Tel.: +31 43 3874502.
E-mail address: j.geurts@mumc.nl (J. Geurts).
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Aetiology of implant related infection has been explained by the
concept of the ‘‘race for the surface’’ by Gristina in 1987.9 Microbial
adhesion and bioﬁlm growth compete with tissue integration. If
tissue cells are ﬁrst to cover the surface of the implant, it will be
less susceptible to bacterial colonisation. If, on the other hand, the
race is won by the bacteria, they will cover the implant by a bioﬁlm
and will be less accessible for the natural host immunologic
response and also for antibiotics. Therefore, bioﬁlm formation
makes antibiotic treatment by itself insufﬁcient for eradication of
the infection. Also, device-associated bioﬁlms represent a focus of
infection from which individual cells or clusters of cells may
detach, resulting in bloodstream infection, emboli and metastatic
spread.10 Diagnosis of infection is also more troublesome and
requires new techniques like sonication to break up the bioﬁlm in
order to identify the pathogen.11
Inoculation of an implant can occur directly at the time of
surgery and manifest itself acutely or late. In a later phase, it can
also occur through seeding at the time of haematological spread
(bacteraemia). A third pathway is through spread from an adjacent
infectious focus.12
Zimmerli and Ochsner classiﬁed periprosthetic joint infections as
early (those that develop less than 3 months after surgery), delayed
(3–24 months after surgery), or late (more than 24 months after
surgery).13 If infection occurs in the early timeframe, it is most likely
due to bacterial contamination at the time of surgery and usually not
very likely to hamper the bone-implant interface. Delayed infections
are also most likely caused by contamination during implantation
and have a low grade character haematogeneous infections in
Fig. 1. Cavity of a femur, after debridement of osteomyelitis full packed with
gentamicin PMMA beads. The relative large surface of the beads facilitates the
diffusion of much gentamicin and the creation of a high local gentamicin
concentration in the haematoma and the bone tissue, above the MIC value of most
causative bacteria.
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manifestations of infection may be low grade infections since the
operation or as a result of haematogenous spread. The haemato-
genous infections are due to a bacteremia with a high dose of
virulent bacteria, caused mostly by an urinary tract or dental
infection, and they can be caused by various pathogens.14 Treatment
options are dictated by this timing and this can be decisive in being
able to save an implant or having to remove it.
Infection: treatment modalities
Two distinct clinical type of infections can be distinguished:
superﬁcial and deep. A superﬁcial infection is an infection situated
above the fascia layer. The criteria for deep infection have been
deﬁned by the Centres for Disease Control (CDC) as follows: a
major infection extending through the deep fascia with purulent
discharge complicated by spreading cellulites, systemic upset,
positive or negative cultures from the deep tissues, pockets of pus
or wound breakdown.39 The challenges of dealing with infection
become far greater when the infection is deep since the implant
itself is then infected and the bone-implant interface is at risk.
Diagnosis is through imaging, blood samples and aspiration,
although negative aspiration is no proof for absence of infection.8
The two different types of infection are tackled with different
treatment strategies, so the diagnosis of either is of utmost
importance.15 Superﬁcial infections can usually be managed by
systemic administration of antibiotics, but sometimes surgery is
needed consisting of debridement and pulsatile lavage. It may be
difﬁcult to judge preoperatively or peroperatively if the infection is
limited to superﬁcial tissues or is also deep. If the treatment of the
superﬁcial infection proves un-successful there is a need for
subsequent debridement of the joint.16 Deep infections require
always antibiotics and surgical debridement, with pulse lavage,
addition of gentamicin beads or ﬂeeces, exchange of implant parts
and in the worst case scenario removal of the implant.40 In the case
of total joint arthroplasty one and two-stage revision can be
considered. Literature reports beneﬁts and drawbacks for both
strategies, but there are currently no clear guidelines on which is
best. It has been shown that when diagnosis is swift and treatment
started early, implants can often be saved and remain in situ.41,42
There is no clear consensus in literature on when an implant has to
be removed or how long one can try to save it. Some authors report
salvage of implants of up to two months after initial diagnosis of
infection, where others advocate immediate removal.13
Antibiotics are a crucial part of the treatment in implant-related
infections. Generally, intravenous treatment is necessary in the
early stages and when inﬂammatory parameters improve, a switch
can be made to oral treatment. Moran et al.17 found organisms
most frequently isolated in implant-related infections to be
coagulase-negative staphylococci (CoNS, 47% patients) and meth-
icillin-sensitive Staphylococcus aureus (MSSA, 44% patients). Eight
percent grew methicillin-resistant Staphylococcus aureus (MRSA),
8% grew aerobic Gram-negatives and 7% grew anaerobes. Thirty-
seven percent grew multiple organisms.
Antibiotic treatment needs to be adjusted and narrowed when
the causative organism is identiﬁed. Important in implant related
infections is the use of rifampicine (in combination with penicillin
or cephalosporin) to eradicate bacteria in the bioﬁlm. There is no
urgency to add rifampicine from the start, but preferably only after
a few days of initial antibiotic treatment, so that most of the
bacterial load is already eliminated.
When local antibiotic therapy is indicated, polymethylmetacry-
late (PMMA) beads are considered the gold standard. High local
antibiotic concentrations can be achieved (exceeding the minimal
inhibitory or bactericidal concentrations of most pathogenic
organisms) and the rate of release is constant and no nephrotoxicityor other systemic side-effects could be shown.18–20 Requirements
for the antibiotics being used are heat-resistance and water
solubility. Beads have to be removed, which requires a second
operation, which might be undesirable in some cases. When a total
joint arthroplasty has to be removed, another option is a PMMA
spacer containing antibiotics. Beneﬁts of such an approach include
restoration of the anatomy whilst awaiting reimplantation surgery,
and keeping the patient mobile. However, the release of antibiotics is
a lot lower than levels obtained by the implantation of beads20,43.
This is because the total surface area of the beads is a lot larger than a
spacer (Fig. 1). Moreover, beads release about 24% (11%) of their
antibiotic content (mini-beads even up to 93  1.4%),19 whereas the
content released by the spacers is signiﬁcantly smaller.20,21 Also,
unexpected bone loss can occur.22We therefore advise the use of beads
in a ﬁrst stage, eradicating the bulk of the bacterial load, and switching
to a spacer in the next phase if indicated.
Favouring a spacer in some cases is driven by the fact that a
spacer can be a deﬁnitive treatment for some patients who are
unable to undergo any further interventions due to an unaccept-
able high perioperative risk proﬁle. Using a drain or not when local
antibiotics are applied is the surgeon’s choice. Having a small
residual haematoma increases local concentration of the antibiotic
and therefore, in our opinion, a drain is favoured in the ﬁrst 24 h.
Both beads and spacers can be loaded with a variety of
antibiotics. Most common used are gentamicin, tobramycin and
vancomycin. The most important prerequisites for antibiotics
incorporated in cement are heat-resistance and good water-
solubility.
Other methods of local antibiotic release also exist, such as
antibiotic-loaded porous hydroxyapatite blocks,23 gentamicin-
collagen ﬂeeces24 or antibiotic-loaded calcium sulphate pel-
lets.44,45
Future developments are also focusing on loading the implant
surface with antibiotics and antimicrobial coatings.
Infection: bone graft substitutes in active or suspected
infection-the challenges
Concepts
When using biomaterials in active or suspected infection
various considerations have to be made. First of all the proper
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antibiotic release, the depth of antibiotic penetration in surround-
ing tissues and the release proﬁle of the antibiotic agent (burst or
prolonged). Secondly there is a need to assess the effect of bone
graft substitute properties such as composition, hydrophilic or
hydrophobic behaviour, porosity and surface area on these
antibiotic release parameters.
Thirdly the level of evidence of most materials is still limited
and this clearly needs to be taken into account.
It is generally accepted that for the treatment of infection, the
type of pathogen and the time of infection occurrence determine
the antibiotic agent or agents to be administered. Ideally a high
concentration (MIC – minimum inhibitory concentration) release
pattern of antibiotics is needed in the ﬁrst 1–2 days and thereafter
a prolonged release of a lower MIC should be maintained for
another 4 weeks. The penetration depth of the antibiotic agent
should be 1 cm in the surrounding tissues and the concentration as
high as possible without leading to environmental toxicity.46 The
maximum concentration when using PMMA beads can be as high
as 200–400 mg/ml at day three, in general about100 times the MIC
value can be achieved.46 There is a large variance in mechanical
and biological behaviour between materials such as bioglass,
collagen-ﬂeeces and various calcium phosphate (Ca–P) based
materials. Properties of bone graft substitute materials have a
profound effect on the antibiotic binding and release proﬁle.
Composition of the bone graft substitute material determines a
large proportion of its susceptibility and ability to bind antibiotic
agents on its outer surface or throughout its structure and has a
direct inﬂuence on cellular response.25 Whether a material is
hydrophilic or hydrophobic has a big impact on release proﬁles.34
Strength and biological behaviour of bone graft substitutes are
much inﬂuenced by the porosity and surface area properties and in
turn they also have a profound effect on the ability to bind and
release antibiotic agents.26
Materials
Synthetic bone graft substitutes are usually osteoconductive
and consist of calcium phosphate Ca–P (either hydroxyapatite (HA)
or tricalcium phosphate (TCP) or a combination of both)
components.25 All Ca–P synthetic porous substitutes share
numerous advantages over autografts and allografts including
their unlimited supply, easy sterilisation, lack of disease transmis-
sion, and long-term storage. Using Ca–P bone graft substitute
materials as a scaffold for drug delivery in the treatment of
infection has primarily been performed after the development of
Ca–P cements.47 These types of materials are similar in composi-
tion to bone mineral content and they are biocompatible, bioactive
and osteoconductive and have the unique capability to be able to
absorb several chemical (pharmacological) substances on their
surface. In contrast to Ca–P granules or beads where pharmaco-
logical agents do only absorb on the surface, calcium phosphate
cements can incorporate pharmacological agents throughout their
entire structure.48
Many authors have investigated impregnation of antibiotics
onto Ca-P granules and their subsequent antibiotic release
proﬁles.26–32 However, clinical evidence is still limited. Recently
a new resorbable hybrid bead composed of Ca–P and calcium
sulphate (Heraﬁll1) containing gentamicin sulphate as a protec-
tion against bacterial colonisation was marketed and intended to
ﬁll bone voids that result from surgical debridement after post-
traumatic, post-operative and hematogenic osteomyelitis.
Although of interest, clinical data in well controlled trials is not
yet available. Next to Ca–P materials also bioglass and collagen
sponges loaded with antibiotics have been used for infection
treatment.24,36,37Bioactive silicate glasses were the ﬁrst man-made inorganic
materials engineered to bind to bone tissue.33 These inorganic
materials provide an ideal environment for colonisation, prolifer-
ation, and differentiation of osteoblasts to form new bone
exhibiting mechanically strong attachment to the implant surface.
Moreover, reactions on the bioactive glass surface induce the
release of critical concentrations of soluble ions, for example, Si, Ca,
and P, which has been shown to lead to favourable intracellular and
extracellular responses promoting rapid bone formation.49
Collagen ﬂeeces loaded with antibiotics are able to release a
high amount of their antibiotic in the very early stages of
implantation and do not have to be removed in a second
operation.24,34 However, they are generally not able to release
antibiotics for a sustained time period. Variations between the
various products exit (days to 2–4 weeks) and their release can be
inﬂuenced by the rate of material resorption.
Infection: bone graft substitutes in active or suspected infection
– clinical experience
The two key elements of a local antibiotic delivery system are
the delivery vehicle and the antimicrobial agent.35 For adequate
local delivery the antibiotic must bind and be released adequately
from the delivery vehicle and it should also be active against the
targeted microbial pathogens.
To be able to adequately compete for the treatment of infection
with PMMA beads and spacers, bone graft substitutes should be
able to provide same efﬁcacy, have both a burst and prolonged
antibiotic release proﬁle. When they are also resorbed without the
need of surgical removal they truly offer beneﬁcial properties in
clinical practice.
However, an introduction of Ca–P bone graft substitute
materials in an infected or a suspective infected site also brings
an inherent risk. The scaffolds might provide bacteria the perfect
opportunity to invade and encapsulate themselves into the Ca–P
scaffold thereby prolonging the infection.
Soaking up antibiotics into a porous Ca–P scaffold has led to a
variety of amounts of antibiotic to be incorporated and different
release proﬁles. In clinical practice a ﬁne balance should exist
between antibiotic release and its associated environmental
toxicity. Also combination of Ca–P bone graft substitutes with
antibiotics is not universal and their performance in one clinical
site may not necessarily predict their performance in another
clinical indication. Thru level 1 clinical evidence of Ca–P bone graft
substitute efﬁcacy in randomised clinical trials is scarce.
Good clinical results in the treatment of osteomyelitis are
reported with a bioglass material (BonAlive1) in a small patient
cohort.36 Bioglass is also believed to have angiogenic effect which
may be beneﬁcial in late infection healing treatment.37
Collagen ﬂeeces (such as Septocoll1) with antibiotics have been
extensively used with reasonable results.34 Concerning collagen
ﬂeeces loaded with antibiotics one drawback needs mentioning.
Although no reports in literature can be found, a lot of users cite a
tendency for ﬂeeces to provoke prolonged wound drainage during
week 2–4 postoperative, difﬁcult to distinguish from genuine,
persisting infection. The same disturbing secretion has been
described with Ca–P bone substitutes.50
Ongoing research does not solely focus on bone graft substitute
materials. The combination of antimicrobial coatings on implants
with biomimetic HA coatings is also rapidly advancing.32,38
Especially in the early stage of implantation, it should protect
the grafted site against microbiological pathogens. Teller et al.32
reported the release kinetics of gentamicin after loading from a
biomimetic HA coating (BONITmatrix). Release kinetics of the
loaded Gentamicin was investigated and for BONIT matrix a high
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investigated 70-day period.32
Conclusion and discussion
Infection of any foreign material, implanted in the human body, is
a serious and difﬁcult to treat problem. A lot of revisions deemed
‘‘aseptic’’, are in fact low-gradeinfections, so totalnumber of infected
implants is most likely underreported. Bioﬁlm formation renders
bacteriauntouchablefor mostcurrentantibiotics and posesanadded
problem in treatment. Since most infections occur at implantation,
sterile technique remains of utmost importance. It is also important
to differentiate superﬁcial from deep infections, since treatment is
different for both and much more invasive and demanding for the
patient involved. In this regard we deem that better treatment
guidelines from surgical societies are warranted. Larger databases
for implant infection registration and subsequent treatment efﬁcacy
offer ways to compare different treatment modalities in larger
cohorts. They also offer opportunities for further treatment
enhancement and we advocate that these should be initiated in a
multinational manner. In any infection case, effort must be made to
try and retain the original implant. Any surgical treatment requires
adjuvant intravenous or oral antibiotic treatment.
The choice of the optimal bone substitutes for treatment of
infection is therefore not always an easy one, and largely depends
on the clinical application and its associated biological and
mechanical needs. Not all bone graft substitutes will perform
the same way, and their performance in one clinical site may not
necessarily predict their performance in another site. From our
perspective PMMA beads remain the golden standard but
interesting new materials and treatment techniques are on the
brink of clinical implementation. Proper examination of their
feasibility and effect in well-designed randomised trials is
essential to value their clinical application. It remains important
to realize that new treatment options can improve clinical
outcomes but cannot replace the need for prophylactic efforts
and prevention of infection occurrence.
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